Related Experiment Video
Updated: May 10, 2026

Studies of Chaperone-Cochaperone Interactions using Homogenous Bead-Based Assay
Published on: July 21, 2021
Contributions of co-chaperones and post-translational modifications towards Hsp90 drug sensitivity
Annerleim Walton-Diaz1, Sahar Khan, Dimitra Bourboulia
1Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-1107, USA.
Abstract:
Hsp90 is a molecular chaperone and important driver of stabilization and activation of several oncogenic proteins that are involved in the malignant transformation of tumor cells. Therefore, it is not surprising that Hsp90 has been reported to be a promising target for the treatment of several neoplasias, such as non-small-cell lung cancer and HER2-positive breast cancer. Hsp90 chaperone function depends on its ability to bind and hydrolyze ATP and Hsp90 inhibitors have been shown to compete with nucleotides for binding to Hsp90. Multiple factors, such as co-chaperones and post-translational modification, are involved in regulating Hsp90 ATPase activity. Here, the impact of post-translational modifications and co-chaperones on the efficacy of Hsp90 inhibitors are reviewed.
Insights
Heat shock protein 90 (Hsp90) is a key cancer target. This review examines how co-chaperones and post-translational modifications affect Hsp90 inhibitor efficacy in cancer treatment.
Area of Science:
- Molecular Biology
- Oncology
- Biochemistry
Background:
- Heat shock protein 90 (Hsp90) is a molecular chaperone crucial for stabilizing oncoproteins driving cancer progression.
- Hsp90 is a validated therapeutic target for various cancers, including non-small-cell lung cancer and HER2-positive breast cancer.
- Hsp90's function relies on ATP binding and hydrolysis, making its ATPase activity a key target for inhibitors.
Purpose of the Study:
- To review the regulatory roles of co-chaperones and post-translational modifications (PTMs) on Hsp90.
- To analyze how these regulatory factors influence the effectiveness of Hsp90 inhibitors in cancer therapy.
Main Methods:
- Literature review of studies investigating Hsp90 regulation.
- Analysis of research on Hsp90 inhibitors and their mechanisms of action.
- Synthesis of data on the interplay between Hsp90, co-chaperones, PTMs, and drug efficacy.
Main Results:
- Co-chaperones and PTMs significantly modulate Hsp90's ATPase activity and client protein interactions.
- These regulatory mechanisms can impact the sensitivity and resistance of cancer cells to Hsp90 inhibitors.
- Understanding these modulations is critical for optimizing Hsp90-targeted cancer therapies.
Conclusions:
- Hsp90 inhibitors represent a promising therapeutic strategy for cancer treatment.
- The efficacy of Hsp90 inhibitors is influenced by cellular factors including co-chaperones and PTMs.
- Further research into these regulatory networks will be essential for developing more effective Hsp90-targeted drugs.
Related Concept Videos
Bacterial Protein Maturation
Molecular Chaperones and Protein Folding
The...
Molecular Chaperones and Protein Folding
The...
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein.
Protein Complex Assembly
Many viruses self-assemble into a fully functional unit using the infected host cell to...
Post-translational Translocation of Proteins to the RER
Targeting proteins to the ER
Hsp40 and Hsp70 chaperone molecules bind the translated proteins in the cytosol to prevent their folding. The chaperone binding helps to keep the signal...

